Canada Biotechnology & Medical Research

enGene Therapeutics Inc. (ENGN)

Track

Track

Interim Chief Medical Officer William Grossman executed a purchase of 5,102 shares valued at $10,050.94 on September 22, 2026. This represents the sole insider trading activity within the last ninety days. The company recently reported results exceeding expectations, with the stock currently trading near the midpoint of its annual range.
Ticker: ENGN Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for enGene Therapeutics Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.4
Grossman William Interim Chief Medical Officer Executive Director
Transaction date
Purchase
Price
272.21
Quantity 4,927 +19.9%
Value US$2,542,504
3.1
Cooper Ronald Harold Wilfred Chief Executive Officer Executive Director
Transaction date
Purchase
Price
5.70
Quantity 10,000 +inf%
Value US$57,000
Cheung, Anthony Senior Officer of Issuer Officer
Transaction date
Purchase
Price
0.89
Quantity 52,940 +106.0%
Value US$47,117
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-24 2026-09-22 B Purchase
3.4
Grossman William

Interim Chief Medical Officer

Executive Director
4,927 +19.9%
272.21
US$2,542,504 		4,927 +19.9% 272.21 US$2,542,504
2024-11-01 2024-10-30 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
61,999 +19.9%
431.34
US$2,073,235 		61,999 +19.9% 431.34 US$2,073,235
2024-10-18 2024-10-08 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
42,467 -28.8%
486.68
US$3,667,374 		42,467 -28.8% 486.68 US$3,667,374
2024-10-18 2024-10-07 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
11,844 +0.5%
6.55
US$77,531 		11,844 +0.5% 6.55 US$77,531
2024-10-18 2024-10-04 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
5,997 +0.2%
6.54
US$39,242 		5,997 +0.2% 6.54 US$39,242
2024-10-18 2024-10-03 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
5,769 +0.2%
6.48
US$37,397 		5,769 +0.2% 6.48 US$37,397
2024-10-18 2024-10-02 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
10,153 +0.4%
6.37
US$64,697 		10,153 +0.4% 6.37 US$64,697
2024-10-18 2024-10-01 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
35,279 +1.5%
6.44
US$227,158 		35,279 +1.5% 6.44 US$227,158
2024-10-18 2024-09-30 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
341,332 +16.6%
6.34
US$2,163,362 		341,332 +16.6% 6.34 US$2,163,362
2024-10-18 2024-09-27 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
3,243 +0.2%
6.38
US$20,688 		3,243 +0.2% 6.38 US$20,688
2024-10-18 2024-09-27 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
38,396 +1.9%
5.94
US$228,011 		38,396 +1.9% 5.94 US$228,011
2024-10-01 2024-09-27 B Purchase
3.1
Cooper Ronald Harold Wilfred

Chief Executive Officer

Executive Director
10,000 +inf%
5.70
US$57,000 		10,000 +inf% 5.70 US$57,000
2024-04-22 2024-04-22 S Sale
3.8
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
Large shareholder
47,854 -1.6%
15.00
US$717,810 		47,854 -1.6% 15.00 US$717,810
2024-04-22 2024-04-19 S Sale
3.8
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
Large shareholder
100 -0.0%
15.00
US$1,500 		100 -0.0% 15.00 US$1,500
2024-04-22 2024-04-18 S Sale
3.8
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
Large shareholder
4,575 -0.1%
15.01
US$68,671 		4,575 -0.1% 15.01 US$68,671
2024-03-20 2024-03-18 B Purchase
Cheung, Anthony

Senior Officer of Issuer

Officer
52,940 +106.0%
0.89
US$47,117 		52,940 +106.0% 0.89 US$47,117
2024-10-18 2023-12-29 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
9,620 +0.5%
9.09
US$87,451 		9,620 +0.5% 9.09 US$87,451
2024-10-18 2023-12-29 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
400 +0.0%
8.30
US$3,320 		400 +0.0% 8.30 US$3,320
2024-10-18 2023-12-28 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
5,050 +0.3%
7.69
US$38,827 		5,050 +0.3% 7.69 US$38,827
2024-10-18 2023-12-27 B Purchase
2.4
Forbion Growth Opportunities Fund I Cooperatief U.A.
Large shareholder
2,750 +0.1%
7.17
US$19,711 		2,750 +0.1% 7.17 US$19,711
Explore more

More insider trading research around enGene Therapeutics Inc.

More insider trades in Canada
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America